| Date | Title | Description |
| 23.08.2023 | FORE Biotherapeutics raised a $75M Series D and announced an interim CEO | Update: Details about funding and employee count from a FORE spokesperson have been added. (8/23/23, 4:15 p.m.)
University City-based FORE Biotherapeutics raised $75 million in a Series D round, the biotech company announced today. The roun... |
| 08.06.2023 | Finance: Elevation Oncology Announces Pricing of $50M IPO | What You Should Know:
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet med... |
| 28.07.2022 | Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures | What You Should Know:
Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior ... |
| 10.01.2022 | Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones | NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today highlighted i... |
| 12.11.2021 | Elevation Oncology Reports Third Quarter 2021 Financial Results | NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced fin... |
| 20.10.2021 | Elevation Oncology : Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer | NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the... |
| 12.08.2021 | Elevation Oncology Reports Second Quarter 2021 Financial Results | NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced fin... |
| 12.08.2021 | Elevation Oncology Reports Second Quarter 2021 Financial Results | |
| 25.06.2021 | Elevation Oncology : Announces Pricing of Initial Public Offering | NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the... |
| 24.06.2021 | Elevation Oncology Announces Pricing of Initial Public Offering | |
| 17.06.2021 | Elevation Oncology Announces Appointment of Joseph Ferra as Chief Financial Officer | |
| 10.04.2021 | Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signalin... | |
| 06.04.2021 | Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models | |
| 16.03.2021 | Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study | NEW YORK and FORT MYERS, Fla., March 16, 2021 /PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, I... |
| 24.11.2020 | Healthcare startups that raised funding week of Nov 16-20 | Sofia, Metagenomi, Strava, Elevation Oncology among the companies landing fresh capital
Adaptilens: Adaptilens is a Boston-based maker of an injectable lens for improving vision. Adaptilens has raised $1.6 million in seed funding led by Pil... |
| 19.11.2020 | Elevation Oncology Raises $65M in Series B Financing | Elevation Oncology, a New York-based clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, raised $65m in Series B financing.
Backers included new investors... |
| 19.11.2020 | Elevation Oncology secures $65M Series B | Elevation Oncology has raised $65 million in a round co-led by VenBio Partners and Cormorant Asset Management. The New York-based company is the operator of a drug discovery platform intended to develop precision medicines for cancer treatm... |
| 18.11.2020 | Elevation Oncology Raises $65M Series B Financing | Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series B financing of $65 million led by new investors, venBio... |
| 18.11.2020 | Elevation Oncology Inks $65M Series B Financing |
NEW YORK, NY, Elevation Oncology announced a Series B financing of $65 million led by new investors, venBio Partners and Cormorant Asset Management.
>> Click here for more funding data on Elevation Oncology
>> To export Elev... |
| 18.11.2020 | Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer | NEW YORK, NY – November 18, 2020 – Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series B financing of $65 m... |
| 18.11.2020 | Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer | |
| 18.11.2020 | Elevation Oncology Raises $65M Series B | Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series B financing of $65 million led by new investors, venBio... |
| 22.07.2020 | Elevation Oncology Raises $32.5M in Series A Funding | Elevation Oncology, a NYC-based clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, raised $32.5M in Series A financing.
The round was led by Aisling Capi... |
| 21.07.2020 | Elevation Oncology Emerges from Stealth with $32.5M Series A | Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the launch of the Company with a $32.5M Series A financing, init... |
| 21.07.2020 | Elevation Oncology Emerges With $32.5M |
NEW YORK, NY, Elevation Oncology announced today the launch of the Company with a $32.5 million Series A financing.
>> Click here for more funding data on Elevation Oncology
>> To export Elevation Oncology funding data to PD... |
| 21.07.2020 | Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations | – $32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners –
– Registration-Enabling Phase 2 CRESTONE Study Now Enrolling Patients with Solid Tumors of... |
| - | Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study | NEW YORK and FORT MYERS, Fla., March 16, 2021 /PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, I... |
